- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- General population
- Infants (<1 year)
- Children (1-11 years)
- Hospital
- Primary care
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Human metapneumovirus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Steroids
- Dexamethasone
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Monkeypox virus
- Pharmacological intervention
- Vaccination
- VAC∆6
- General population
- Infants (<1 year)
- Children (1-11 years)
- Community
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Rhinovirus
- Human metapneumovirus
- Parainfluenza Virus
- Enterovirus
- Seasonal coronavirus
- Bocavirus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Oxygen therapy
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
- Tixagevimab/Cilgavimab
- Casirivimab/Imdevimab
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Dietary
- Lifestyle intervention
- Curcuma
- Adults (18-64 years)
- Elderly (≥65 years)
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Tocilizumab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Hantavirus
- Leptospira spp.
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Blood sample
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Non pharmacological intervention
- Dietary
- Lifestyle
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Outpatient clinic
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome